Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (February 2025)
32 slides from Maat Pharma's investor presentation, February 2025
Slide 1: Boosting Survival Through Innovative Immune Modulation
MaaT Pharma Boosting Survival Through Innovative Immune Modulation
Slide 2: Disclaimer
MaaT Pharma. Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors
Slide 3: Management Team
MaaT Pharma. Management Team @ a wt Hervé Affagard Eric Soyer Gianfranco Pittari, Carole MD, PhD Schwintner, PhD Co-Founder & CEO Chief Financial Chief Medical Chief Technology Officer Officer Officer , Celgene | tl Bristol Myers Squibb’ BIO-RAD PHAX|AM Company BIO-RAD cj - Autelus D #3 eurofins s a
Slide 4: Company Overview
Company Overview
Slide 5: MaaT013 in aGvHD: Achieved Primary Endpoint of Phase 3 Study
MaaT Pharma. MaaTO13 in aGVHD: Achieved Primary Endpoint of Phase 3 Study January 2025 5 Registration in Europe Will Spearhead Microbiome Therapies in Oncology Now available: Phase 3 Data in aGvHD from the ARES study Q) Primary endpoint: unprecedented, GI-ORR* of 62% in patients having previously re
Slide 6: Correcting Dysbiosis: a New Pillar in Oncology
MaaT Pharma. Correcting Dysbiosis: a New Pillar in Oncology Dysbiosis and disease ° == Loss of microbial diversity Increase in pathogens Reduction of microbial metabolites Associated with multiple conditions Number of bacterial OTUs in patients fy 3 16 28 Days after first MaaT013 treatment Microbiot
Slide 7: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma. January 2025 7 Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates ‘ r ggat X Native Ecosystem Co-cultured Ecosystem In-house Production Driving near-term value Progressing next-generation Leading capabilities in full ecosystem with the donor-derived MET-N platform co-c
Slide 8: A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset
>» MaaT Pharma. January 2025 8 A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset Program Indication Market potential Preclinical Phase 1 Phase 2 Phase 3 MAA Status © Upcoming milestone MaaTO13 IL: 10k patients’ endpoint met Mid 2025 2L: 5K patients’ 3L: 3K patie
Slide 9: References
• • • Smith PM et al, Science 2013; Sun M et al, Nat Commun 2018; Gaudier E et al, AJPGLP 2004; Furusawa Y et al, Nature 2013; Arpaia N et al, Nature 2013; Mathewson ND et al, Nat Immunol 2016 • • • Jenq RR et al, Biol Blood Marrow Transplant 2005; Taur Y et al, Blood J Am Soc Hematol 2014 • • • M.
Slide 10: MaaT013 in aGvHD
MaaT0l13 in aGvHD
Slide 11: Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)
January 2025 1 Understanding and Addressing Acute Graft-versus-Host Disease (aGVvHD) ‘ — Asignificant complication following allogeneic hematopoietic stem cell transplantation (Allo-HSCT) — Mayoccur in 50% of patients undergoing Allo-HSCT, presence detected typically within the first 100 days post-t
Slide 12: aGvHD Refractory to Steroids and Ruxolitinib: A Substantial Unmet Medical Need
aGvHD Refractory to Steroids and Ruxolitinib (3"¢ line treatment): A Substantial Unmet Medical Need Requiring Innovative Solutions 12 Treatment Paradigm oS) Corticosteroids are the 1** line treatment, but approximately 50% of patients do not achieve a sustained response oS) ruxolitinib is approved a
Slide 13: ARES: a Pivotal Phase 3 Trial Exploring MaaT013 in 3rd-Line aGvHD
LO January 2025 13 ARES: a Pivotal Phase 3 Trial Exploring MaaT013 in 3°¢-Line aGVHD Following ARES Steroid and Ruxolitinib Failure OT + can Treatment Period Di, 5, 10 Primary follow-up Long-term follow-up 66 Patients . > Screening with SR/RR-Gl-aGvHD (PAKK@PA) MaaT013 administration Inclusion crite
Slide 14: ARES Patients: Baseline Characteristics
© MaaTO013 «aGvHD ODDEMA/FDA c January 2025 14 ARES patients: Baseline Characteristics Patients characteristics at baseline All patients receiving MaaT013 (n=66) Median age, years (range) 55.5 (24; 76) Gender n (%) Male: 35 (53%) Female: 31 (47%) Steroid status n (%) Steroid-refractory: 57 (86%) Ste
Slide 15: D28 Response Rate
→ → 80 CR D28 Response rate (%) 62% 64% VGPR • 60 PR 40 • 20 0 GI-ORR ORR
Slide 16: ARES Patients D28 GI-Responders vs Historic 3L
→ → 59% 54% ARES patients D28 GI-responders Historic 3L All patients 20% 15% (Abedin et al. 2021) D28 GI-non responders
Slide 17: Early Access Program: Meeting Critical Needs in GvHD Today
January 2025 7 Early Access Program: meeting critical needs in GVHD today and shaping the future Patients First + Unmet medical need: no approved or efficacious treatment in 3L and beyond + Patients with dismal prognosis Supply chain & Manufacturing + MaaT013 shipped to 10 countries * 2distribution
Slide 18: Clear Regulatory Path for MaaT013 in Third Line Refractory aGvHD
18 january Clear Regulatory Path for MaaT013 in Third Line Refractory aGvHD PinEvrope ©) Eligibility of MaaT013 for the centralized procedure confirmed by EMA (Medicinal product status) and rapporteurs and co-rapporteurs appointed io) Target filing of the EMA Marketing Authorization Application for
Slide 19: A Multi-Asset Platform Focused on Oncology
A Multi-Asset Platform Focused on Oncology
Slide 20: Phoebus: MaaT033 Phase 2b RCT
>) MaaT033« Allo-HSCT January 2025 20 Phoebus: MaaT033 Phase 2b RCT Potential Adjunctive Treatment for Patients Receiving Allo-HSCT Visit] Visit2 15-21deys Visit 3 Visit 6 Visit 10 D-21 D-7 D-O Neutrophilrecovery D+21 M+3 M+12 = >) PreAlloHSCT 7 Post Allo-HSCT v pues C) exteenens CO) © Ci a en week
Slide 21: MaaT013 + IO in Melanoma: Overcoming Primary Resistance
MaaTO13 + IO- Melanoma Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance Immune Checkpoint Inhibitors (ICI) significantly improve outcomes in solid tumor patients Primary Resistance Rate to ICIs Lung Cancer (NSCLC) Gia 35-40 % > Urgent n
Slide 22: MaaT013 Evaluated in Phase 2a Randomized Trial in Melanoma
MaaTO1: noma January 2025 MaaT013 Evaluated in Phase 2 Randomized, Multicenter Clinical Trial in Melanoma Phase 2a PICASSO trial, fully recruited Key study endpoints after 23 weeks of treatment: Investigator Sponsored Trial (Assistance Publique - Hopitaux de Paris) in collaboration with Institut Gus
Slide 23: NCT05889572
→ → → → → → → → → (NCT05889572) → • • •
Slide 24: MET-C Product Generation Driven by Proprietary Predictive AI
>) MET-C ICl and more 6 > ) MET-C Product Generation is Driven by MaaT Pharma’s Proprietary Predictive Al, Eubiotic Score and in vitro and in vivo Validation Processes MaaT034 ‘y MaaT034 & January 2025 24 In silico (>) In vitro (>) HIT Products LEAD Products Donor-independent (MaaT03X) ecosystem can
Slide 25: Hemato-oncology Franchise Driving Value
Hemato- oncology Franchise Driving Value
Slide 26: MaaT013 Addressable Market and Revenues
© MaaT013+ aGvHD January 2025 26 MaaT013 Addressable Market and Revenues Addressable market in 3L Estimated Annual Revenues i =~ ~3,000 patients | 65% Market penetration | 3L GI-SR-RR/I-aGvHD 3L GI-SR-RR/I-aGvHD (~2,000 patients) Ruxolitinib : ~70% MS in the US within 2 years of approval Addressable
Slide 27: Realizing Value through Partnership
MaaT Pharma. Realizing Value through Partnership: January 2025 27 Aligning Innovation with Unmet Medical Needs in Hematology Unique Franchise Opportunity Avery meaningful market opportunity @) Unique immunosuppressant-sparing, microbiome-based approach @) Well defined target population for both prod
Slide 28: End-to-End In-house cGMP Manufacturing Capabilities
End-to-End In-house cGMP Manufacturing Capabilities
Slide 29: Europe's Largest Manufacturing Facility for Microbiome Ecosystem Therapies
AMET January 2025 29 Europe’s Largest ‘ Leading microbiome therapies fully integrated Specia | ized cG M P manufacturing and development platform: . streamlined product development, scaleup and GMP Manufacturing eS Facility for Microbiome Option to expand manufacturing facilities to double A dedicat
Slide 30: Newsflow & Funding Opportunities
Newsflow & Funding Opportunities
Slide 31: Several Major Near-Term Value Inflection Milestones
MaaT Pharma. January 2025 31 Several Major Near-Term Value Inflection Milestones | GvHD | MA, MaaT013 GVHD | Apollo Ph3FPIQ425____! | GvHD | Apollo Ph3resultsH227 [Maatoss © nc , PMaatoas 7, | HSOT | Phoebus Ph2b DSMB : | HSOT| Phoebus Ph2bLPIQ226_| _HSCT | Phoebus Ph2b OS resultsH2 27 _| | MaaT033
Slide 32: Thank you
Thank you